Table 5.
White blood cell analysis.
| Day -2 | Day 5 | Day 10 | |
|---|---|---|---|
| Lymphocytes | Mean ( ± SD)# | Mean ( ± SD) | Mean ( ± SD) |
| Control | 1819.9 ( ± 585.6) | 2138.3 ( ± 649.6) | 2091.5 ( ± 357.3) |
| Foralumab/Dexa | 1770.8 ( ± 431.2) | 3397.9 ( ± 1384.3) | 2190.8 ( ± 666.2) |
| Foralumab | 1722.6 ( ± 623.7) | 2123.2 ( ± 754.9) | 2135.2 ( ± 460.2) |
| *Three group comparison (p-value) | 0.90 | 0.002 | 0.88 |
| †Control - Foralumab/Dexa | – | 0.008 | 0.79 |
| †Control - Foralumab | – | 0.87 | 0.82 |
| †Foralumab - Foralumab/Dexa | – | 0.027 | 0.74 |
| Monocytes | Mean ( ± SD) | Mean ( ± SD) | Mean ( ± SD) |
| Control | 514.8 ( ± 227.1) | 634.2 ( ± 309.9) | 573.8 ( ± 182.9) |
| Foralumab/Dexa | 574.3 ( ± 344.1) | 826.3 ( ± 380.5) | 656 ( ± 339.9) |
| Foralumab | 487.6 ( ± 180.2) | 503.7 ( ± 112.2) | 553.9 ( ± 124.9) |
| *Three group comparison (p-value) | 0.70 | 0.038 | 0.52 |
| †Control - Foralumab/Dexa | – | 0.31 | 0.79 |
| †Control - Foralumab | – | 0.39 | 0.90 |
| †Foralumab - Foralumab/Dexa | – | 0.05 | 0.60 |
| Neutrophils | Mean ( ± SD) | Mean ( ± SD) | Mean ( ± SD) |
| Control | 3236.4 ( ± 1725.8) | 4816.4 ( ± 2169.2) | 4274.9 ( ± 1596.2) |
| Foralumab/Dexa | 4087.2 ( ± 2785) | 5160.6 ( ± 2633.5) | 4197.8 ( ± 1794) |
| Foralumab | 3138.4 ( ± 1734.9) | 3537.8 ( ± 1070.3) | 4308.6 ( ± 1629.7) |
| *Three group comparison (p-value) | 0.48 | 0.14 | 0.98 |
| †Control - Foralumab/Dexa | – | 0.64 | 0.54 |
| †Control - Foralumab | – | 0.24 | 0.71 |
| †Foralumab - Foralumab/Dexa | – | 0.44 | 0.44 |
# Plus–minus values are means ± SD. values are/mm3.
*P-value for three group comparison of change from baseline (day -2) is provided.
†P-values of difference between treatment groups in change from baseline from linear mixed model. Dexa, Dexamethasone.